Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI – Get Free Report) was the target of some unusual options trading activity on Wednesday. Traders purchased 1,002 put options on the stock. This is an increase of 1,791% compared to the average volume of 53 put options.
Institutional Trading of Maravai LifeSciences
A number of hedge funds and other institutional investors have recently made changes to their positions in MRVI. Sprott Inc. acquired a new stake in shares of Maravai LifeSciences during the 3rd quarter worth approximately $29,000. Quantessence Capital LLC acquired a new stake in shares of Maravai LifeSciences during the 3rd quarter worth approximately $31,000. Abel Hall LLC acquired a new stake in shares of Maravai LifeSciences during the 3rd quarter worth approximately $33,000. CIBC Bancorp USA Inc. acquired a new stake in shares of Maravai LifeSciences during the 3rd quarter worth approximately $33,000. Finally, Virtu Financial LLC acquired a new stake in shares of Maravai LifeSciences during the 4th quarter worth approximately $34,000. Institutional investors and hedge funds own 50.25% of the company’s stock.
Maravai LifeSciences Stock Down 6.2%
MRVI stock opened at $4.37 on Thursday. The firm has a 50-day moving average of $3.43 and a two-hundred day moving average of $3.43. The company has a market cap of $1.12 billion, a price-to-earnings ratio of -6.15 and a beta of 0.62. The company has a current ratio of 5.91, a quick ratio of 5.69 and a debt-to-equity ratio of 0.72. Maravai LifeSciences has a 12 month low of $1.95 and a 12 month high of $4.99.
Wall Street Analysts Forecast Growth
A number of research analysts recently weighed in on the stock. Wells Fargo & Company raised their price target on shares of Maravai LifeSciences from $4.50 to $5.50 and gave the company an “overweight” rating in a research note on Friday, May 8th. Deutsche Bank Aktiengesellschaft reaffirmed a “buy” rating and issued a $6.00 price target on shares of Maravai LifeSciences in a research note on Friday, May 8th. Finally, Wall Street Zen raised shares of Maravai LifeSciences from a “sell” rating to a “hold” rating in a research note on Saturday, February 28th. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Maravai LifeSciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $5.50.
Read Our Latest Stock Analysis on Maravai LifeSciences
About Maravai LifeSciences
Maravai LifeSciences Holdings, Inc (NASDAQ: MRVI) is a life sciences company specializing in the development and supply of critical reagents and services for the development and manufacture of biologic therapies. The company’s offerings support a range of applications in genomics, molecular diagnostics, vaccine development and next-generation sequencing. Maravai’s platforms address key challenges in nucleic acid production, protein detection, epigenetic analysis and reagent quality across the biopharmaceutical industry.
Through its product portfolio, which includes proprietary mRNA capping reagents, lipid nanoparticle delivery systems, synthetic oligonucleotides and high-precision assay kits, Maravai enables customers to accelerate research and streamline manufacturing workflows.
Read More
- Five stocks we like better than Maravai LifeSciences
- D-Wave Earnings Looked Weak, But Investors May Be Missing This
- Nebius Upside Expands as AI Feedback Loop Intensifies
- Insider Trades: Okta and Abbott See Buys, Micron Insiders Sell
- Plug Power Flips The Switch On Profitability
Receive News & Ratings for Maravai LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Maravai LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.
